At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09926 AKESO
Market Closed 03-28 16:08:10
74.600
+3.650
+5.14%
High75.800Low71.050Vol16.71M
Open71.050D1 Closing70.950Amplitude6.69%
Mkt Cap66.99BTradable Cap66.99BTotal Shares898.00M
T/O1.24BT/O Rate1.86%Tradable Shares898.00M
P/B11.98ROE-15.63%EPS2.59
52wk High78.75052wk Low26.450P/E28.80
Dividend0.00Div.Yield0.00ROA-6.01%
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Akeso's Penpulimab Receives Nmpa Approval for First-Line Treatment of Nasopharyngeal Cancer
THOMSON REUTERS  ·  03-17
Akeso's Penpulimab Receives Nmpa Approval for First-Line Treatment of Nasopharyngeal Cancer
Akeso, Inc.'s (HKG:9926) Shares Climb 28% But Its Business Is Yet to Catch Up
Simply Wall St.  ·  03-16
Akeso, Inc.'s (HKG:9926) Shares Climb 28% But Its Business Is Yet to Catch Up
Akeso Announces the Publication of Its Phase Iii Clinical Trial Results for Ivonescimab in Head-to-Head Comparison With Pembrolizumab in the Lancet
THOMSON REUTERS  ·  03-07
Akeso Announces the Publication of Its Phase Iii Clinical Trial Results for Ivonescimab in Head-to-Head Comparison With Pembrolizumab in the Lancet
Akeso Announces Completion of Patient Enrollment in the Phase Iii Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma
THOMSON REUTERS  ·  03-06
Akeso Announces Completion of Patient Enrollment in the Phase Iii Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma
Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
THOMSON REUTERS  ·  02-27
Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination With Pfizer's Adcs
THOMSON REUTERS  ·  02-25
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination With Pfizer's Adcs
Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos
Dow Jones  ·  02-24
Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos
Akeso Announces Ind Acceptance for Ak139, a Bispecific Antibody Targeting Il-4RΑ and St2 for Respiratory and Skin Diseases
THOMSON REUTERS  ·  02-14
Akeso Announces Ind Acceptance for Ak139, a Bispecific Antibody Targeting Il-4RΑ and St2 for Respiratory and Skin Diseases
Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in Nsclc
THOMSON REUTERS  ·  02-13
Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in Nsclc
The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ
Dow Jones  ·  02-07
The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ
Akeso Announces the Completion of Patient Enrollment in the Phase Iii Clinical Trial (Harmoni-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-Nsclc
THOMSON REUTERS  ·  02-06
Akeso Announces the Completion of Patient Enrollment in the Phase Iii Clinical Trial (Harmoni-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-Nsclc
Akeso's Gumokimab Monoclonal Antibody (Il-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by Nmpa
THOMSON REUTERS  ·  01-27
Akeso's Gumokimab Monoclonal Antibody (Il-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by Nmpa
Akeso Received Payment for the Development Collaboration on Tagitanlimab
THOMSON REUTERS  ·  01-22
Akeso Received Payment for the Development Collaboration on Tagitanlimab
China Healthcare Sector to Get Policy Boost in 1Q -- Market Talk
Dow Jones  ·  01-07
China Healthcare Sector to Get Policy Boost in 1Q -- Market Talk
GF Securities Starts Akeso at Buy with HK$81.59 Price Target
MT Newswires Live  ·  2024-12-11
GF Securities Starts Akeso at Buy with HK$81.59 Price Target
Akeso's Cervical Cancer Drug Included in China's National Reimbursement Drug List
MT Newswires Live  ·  2024-11-28
Akeso's Cervical Cancer Drug Included in China's National Reimbursement Drug List
BRIEF-Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA
Reuters  ·  2024-11-22
BRIEF-Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA
Akeso's Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma Accepted by Nmpa
THOMSON REUTERS  ·  2024-11-22
Akeso's Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma Accepted by Nmpa
HK's Stock Benchmark Quarterly Review May Add Kuaishou, Pop Mart Stocks
Bloomberg  ·  2024-11-22
HK's Stock Benchmark Quarterly Review May Add Kuaishou, Pop Mart Stocks
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab
THOMSON REUTERS  ·  2024-11-01
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab

Introduction

Company Name.
AKESO
Affiliated Markets:
SEHK
Listing Date:
2020-04-23
Main Business:
Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.
Issue price:
16.180
Invest in Global Markets with Tiger Brokers!
Open App